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VBBACKGROUND Atherosclerosis is an inﬂammatory condition with calciﬁcation apparent late in the disease process.
The extent and progression of coronary calciﬁcation predict cardiovascular events. Relatively little is known about
noncoronary vascular calciﬁcation.
OBJECTIVES This study investigated noncoronary vascular calciﬁcation and its inﬂuence on changes in vascular
inﬂammation.
METHODS A total of 130 participants in the dal-PLAQUE (Safety and efﬁcacy of dalcetrapib on atherosclerotic disease
using novel non-invasive multimodality imaging) study underwent ﬂuorodeoxyglucose positron emission tomography/
computed tomography at entry and at 6 months. Calciﬁcation of the ascending aorta, arch, carotid, and coronary arteries
was quantiﬁed. Cardiovascular risk factors were related to arterial calciﬁcation. The inﬂuences of baseline calciﬁcation
and drug therapy (dalcetrapib vs. placebo) on progression of calciﬁcation were determined. Finally, baseline calciﬁcation
was related to changes in vascular inﬂammation.
RESULTS Age >65 years old was consistently associated with higher baseline calcium scores. Arch calciﬁcation trended
to progress more in those with calciﬁcation at baseline (p ¼ 0.055). There were no signiﬁcant differences between
progression of vascular calciﬁcation with dalcetrapib compared to that with placebo. Average carotid target-to-
background ratio indexes declined over 6 months if carotid calcium was absent (single hottest slice [p ¼ 0.037], mean of
maximum target-to-background ratio [p ¼ 0.010], and mean most diseased segment [p < 0.001]), but did not
signiﬁcantly change if calciﬁcation was present at baseline.
CONCLUSIONS Across multiple arterial regions, higher age is consistently associated with higher calcium scores.
The presence of vascular calciﬁcation at baseline is associated with progressive calciﬁcation; in the carotid arteries,
calciﬁcation appears to inﬂuence vascular inﬂammation. Dalcetrapib therapy did not affect vascular calciﬁcation.
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AU = Agatston Units
BMI = body mass index
CHD = coronary heart disease
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LDL = low-density lipoprotein
MDS = most diseased segment
PET/CT = positron emission
tomography/computed
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SHS = single hottest slice
TBR = target-to-background
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70A therosclerosis is a chronic, systemic,multifocal inﬂammatory disorder, aresponse to the deposition of low-
density lipoprotein (LDL) in the vascular
wall. Although arterial calciﬁcation is
thought to be an actively inhibited but pas-
sive process of mineralization (1), there is
increasing evidence that it is an active and
regulated process, analogous to bone forma-
tion. That supposition is supported by
histological ﬁndings of ectopically formed
bone, the presence of osteoblast- and
osteoclast-like cells, and the secretion of
several bone-related peptides within calci-
ﬁed atherosclerotic lesions. In preclinical
models, inﬂammatory macrophage activity
is seen to precede early osteogenesis (2).
Vascular calciﬁcation serves as a marker
for the extent of atherosclerosis and is predictive of
cardiovascular events and mortality (3,4). Calciﬁca-
tion of the coronary arteries has been extensively
investigated. In clinical practice, coronary calcium
scoring is used to stratify patients’ risk for coronary
heart disease (CHD), providing better discrimination
than classical risk factors alone (4).SEE PAGE 79By comparison, relatively little is known about
vascular calciﬁcation and its progression in other
arterial regions. Contrary to the notion that calciﬁ-
cation represents a stable end stage of the disease,
dynamic microcalciﬁcation may increase the risk of
plaque rupture and clinical events (5). Understanding
this process is important because rapid progression of
calciﬁcation, at least in coronary arteries, is associ-
ated with an increased risk of cardiovascular events.
Current medical therapies, including statins, do not
alter this progression (6,7).
In this study, we investigated the vascular calciﬁ-
cation detected on serial positron emission tomogra-
phy/computed tomography (PET/CT) imaging in the
dal-PLAQUE (Safety and efﬁcacy of dalcetrapib on
atherosclerotic disease using novel non-invasive
multimodality imaging) study, a phase 2 randomized
clinical trial that investigated the effects of the cho-
lesteryl ester transfer protein inhibitor dalcetrapib on
vasculature.n-La Roche AG and holds stock options in The Medicines Compa
La Roche AG, GlaxoSmithKline, Merck, VBL Therapeutics, Novar
ria from F. Hoffmann-La Roche AG. Dr. Rudd has received honora
ted that they have no relationships relevant to the contents of th
received September 4, 2015; accepted October 7, 2015.Speciﬁcally, we hypothesized that: 1) the presence
of classical cardiovascular risk factors would increase
both baseline calciﬁcation and its progression in the
ascending aorta, aortic arch, and carotid and coronary
arteries over 6 months; and that 2) arteries with the
highest baseline calcium levels would undergo the
greatest additional calciﬁcation over the next 6
months.
METHODS
The current study was a post-hoc analysis of the
dal-PLAQUE study. The study design, methods, and
primary results have already been published (8,9).
dal-PLAQUE was a phase 2b, double-blind, random-
ized, placebo-controlled study that investigated
the effect of dalcetrapib on vessel wall inﬂamma-
tion, assessed by 18F-labeled ﬂuorodeoxyglucose
([18F]FDG) PET/CT. Inclusion criteria included men
and women 18 to 75 years of age with known CHD or
who were at high risk thereof (with diabetes or a
10-year risk of CHD events >20% by Framingham risk
scoring [10]) and whose triglyceride concentrations
were #400 mg/dl, low-density lipoprotein cholesterol
(LDL-C) concentrations were <100 mg/dl, or who were
taking maximum tolerated doses of statins and had a
target-to-background ratio (TBR) of 1.6 or higher in an
index vessel (either right carotid, left carotid, or
ascending aorta), as identiﬁed by [18F]FDG uptake
measured by PET/CT during the screening period.
PET/CT IMAGING. Details of [18F]FDG-PET/CT imag-
ing procedures, quantiﬁcation of tracer uptake,
and analyses have been published previously (8).
[18F]FDG-PET/CT imaging of the carotid arteries and
ascending aorta was performed at baseline, as well as
after 3 and 6 months of follow-up.
Arterial [18F]FDG uptake was quantiﬁed by manu-
ally delineating a region of interest on coregistered
transaxial PET/CT images. A circular region of interest
was drawn to encompass the vessel wall on each
contiguous axial segment. Next, the maximum arte-
rial standardized uptake value was determined,
deﬁned as the decay-corrected tissue concentration
of [18F]FDG in kBq/ml, adjusted for the injected [18F]
FDG dose and body weight of the patient. We calcu-
lated TBR from the ratio of the standard uptake value
of the artery compared with that of backgroundny. Prof. Fayad has received research grants from F.
tis, Bristol-Myers Squibb, and Via Pharmaceuticals;
ria from F. Hoffmann-La Roche AG. All other authors
is paper to disclose.
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71venous activity and recorded values for the individ-
ual vessels (aorta and mean right and left carotid
arteries) using previously reported methods (8).
The vessel with the highest maximum TBR at baseline
was considered the index vessel. Mean of maximum
(MeanMax) TBR was the average of the maximal TBR
values from each artery. The most diseased segment
(MDS) was deﬁned as the average maximum TBR of a
group of 3 contiguous slices, centered on the slice
with the highest maximum TBR, the single hottest
slice (SHS). Active slices were deﬁned as those with
TBR >1.6. For the current analyses, we used baseline
values and changes at 6 months in the indexes
described previously for both the index vessel and
the average of both carotid arteries.
ASSESSMENT OF VASCULAR CALCIFICATION. Analysis
was performed using baseline and 6-month CT scans
by an experienced observer (F.R.J.) blinded to both
clinical details and scan order. Unenhanced CT
imaging acquired for localization of [18F]FDG-PET
uptake was loaded into the open-source DICOM
(Digital Imaging and Communications in Medicine)
OsiriX version 4.0 viewer software (OsiriX imaging
software, Geneva, Switzerland) and resampled to a
3-mm transaxial thickness.
Using the freely available calcium-scoring plug-in,
vascular calciﬁcation (on the basis of an attenuation
threshold of 130 Hounsﬁeld units in 3 contiguous
voxels, after the method of Agatston et al. [11]) was
analyzed on consecutive transaxial slices along the
length of the arterial segment. The extent of calciﬁ-
cation was expressed both as a score in Agatston units
and as a volume in cubic millimeters. The measure-
ment of thoracic aortic and coronary artery calciﬁca-
tion from ungated CT studies is accurate and highly
concordant with values derived from gated studies
(12). Paired (baseline and follow-up) studies were
visually compared to ensure that the same length of
artery was analyzed on both scans.
Coronary artery calciﬁcation was scored as the sum
of all 3 epicardial vessels. Ascending aortic calciﬁca-
tion was scored using transaxial slices from the main
pulmonary artery inferiorly to 1 slice below the aortic
arch. Aortic arch calciﬁcation was scored using
transaxial slices from the most inferior slice at which
the ascending and descending aorta were contiguous
to the origin of the great vessels. Calciﬁcation was
scored if it appeared to be in the vascular wall. When
isolated calciﬁcation of the ligamentum arteriosum
was obvious, it was not scored. Carotid arterial
calciﬁcation was assessed bilaterally from the most
inferior slice visible on the CT scan to the base of the
skull and then summed.Coronary calcium was not recorded in those pa-
tients who had previously undergone percutaneous
coronary intervention or coronary artery bypass sur-
gery. If the participant had evidence of prior coronary
bypass surgery, the ascending aorta was not analyzed
due to artifacts from the surgical clips used in fash-
ioning the grafts. If possible, calciﬁcation in the aortic
arch was still scored in such cases, provided there
were no signiﬁcant artifacts from sternal wires or
surgical clips. Noisy CT images of the neck, with ar-
tifacts from dental prostheses, were excluded from
analyses of the carotid arteries.
STATISTICAL ANALYSIS. Descriptive data are me-
dians (interquartile range [IQR]) as well as fre-
quencies with proportions for nominal variables, as
appropriate.
Measurements of progression of vascular calciﬁ-
cation included the absolute differences between
baseline and follow-up; the difference between the
square root (SQRT) of baseline and SQRT of follow-up
score (the SQRT method of Budoff et al. [13]). A cutoff
value of 2.5 was used to identify a change in calciﬁ-
cation from baseline beyond the known interscan
variability of coronary calcium scores, according to
Hokanson et al. (14).
Baseline calcium scores in the presence or absence
of risk factors were compared after SQRT trans-
formation using analysis of variance (ANOVA). Base-
line calcium scores were dichotomized into “zero” and
“non-zero,” and the effect of a nonzero score on pro-
gression of calciﬁcation (absolute change after SQRT
transformation) was analyzed using ANOVA. The ef-
fect of a nonzero score on absolute changes in PET
indices at 3 and 6months were assessed through linear
mixed models with a visit by score interaction. The
effect of dalcetrapib treatment on calcium progression
(absolute change on original scale and also after SQRT
transformation) was analyzed using ANOVA, with
baseline and treatment in the model. Two-sided p
values are reported throughout, with no adjustment
for multiple testing. The lack of adjustment for mul-
tiple testing was pre-planned and was stated in our
statistical analysis plan for all dal-PLAQUE papers
(8,9). Here, we provide raw p values that should be
interpreted in the light of multiple testing.
RESULTS
dal-PLAQUE recruited 130 patients with a median
65 years of age, most of whom (82%) were male.
Baseline demographics are reported in Table 1. After
exclusions, both baseline and 6-month CT images
yielded data for the aortic arch in 98 patients (75%),
TABLE 1 Baseline Demographics
Placebo
(n ¼ 66)
Dalcetrapib
(n ¼ 64)
Overall
(n ¼ 130)
Demographics
Age, yrs 64.6 (61–71) 62.6 (60–68) 63.6 (60–70)
Males 55 (83) 51 (80) 106 (82)
BMI, kg/m2 29.8 (25.5–32.3) 29.6 (25.9–32.1) 29.7 (25.7–32.2)
White 62 (94) 58 (91) 120 (92)
Medical history
Coronary heart disease 54 (82) 57 (89) 111 (87)
Symptomatic coronary
artery disease
5 (8) 5 (8) 10 (8)
Hypertension 48 (73) 47 (73) 95 (74)
Type 2 diabetes 20 (30) 19 (30) 39 (30)
Abdominal aortic aneurysm 2 (3) 3 (5) 5 (4)
Peripheral artery disease 10 (15) 6 (9) 16 (12)
Current smoker 8 (12) 9 (14) 17 (13)
Statin use 61 (92) 52 (81) 113 (87)
Imaging parameters at baseline
Average carotid [18F]FDG-PET/CT
MeanMax TBR 1.76 (1.47–2.10) 1.79 (1.58–2.21) 1.78 (1.50–2.19)
Single hottest slice 1.96 (1.70–2.40) 2.01 (1.83–2.45) 2.00 (1.73–2.44)
Calcium scores, AU
Ascending aorta 0 (0, 0) 0 (0, 0) 0 (0, 0)
Aortic arch 157 (0–797) 166 (0–865) 161 (0–852)
Coronary arteries 16 (0–89) 10 (0–58) 13 (0–83)
Total carotid arteries 100 (0–315) 27 (1–234) 52 (0–267)
Values are median (interquartile range) or n (%).
AU ¼ Agatston units; BMI ¼ body mass index; [18F]FDG-PET/CT ¼ 18F-labeled ﬂuorodeoxyglucose positron
emission tomography/computed tomography; MeanMax¼mean of maximum; TBR¼ target-to-background ratio.
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72the ascending aorta in 80 patients (62%), the carotid
arteries in 102 patients (78%), and the coronary
arteries in 32 patients (25%). Data were included only
when the whole arterial territory was visualized on
both PET and CT scans.
At baseline, the median calcium score in the aortic
arch was 161 (IQR: 0 to 852), 52 (IQR: 0 to 267) in the
combined carotid arteries, and 13 (IQR: 0 to 83) in the
coronary arteries. The median calcium score in the
ascending aorta was 0 (IQR: 0 to 0). Given the large
number of zero scores (71 of 80 participants), it was
not possible to analyze associations between cardio-
vascular risk factors and baseline scores in the
ascending aorta. Across all other arterial territories,
baseline calcium scores were higher in those over
age 65 years than in younger participants (Table 2).
Scores in the aortic arch were signiﬁcantly higher
in those who had ever smoked (329 [IQR: 43 to 1,073]
vs. 0 [IQR: 0 to 551], respectively; p ¼ 0.003 after SQRT
transformation). Calcium scores in the carotid arteries
were higher in those with body mass index (BMI)
#29 kg/m2 than in those with BMI >29 kg/m2 (132
[IQR: 3 to 411] vs. 7 [IQR: 0 to 158], respectively;
p ¼ 0.007 after SQRT transformation), but not else-
where. An LDL-C >80 mg/dl was not associatedwith signiﬁcantly higher baseline calcium scores than
those with LDL-C #80 mg/dl. Additionally, high-
density lipoprotein cholesterol (HDL-C) concentra-
tions#40mg/dl were not signiﬁcantly associated with
higher calcium scores than concentrations >40 mg/dl.
A history of CHD, hypertension, type 2 diabetes,
peripheral arterial disease, ormetabolic syndromewas
not associated with higher baseline calcium scores in
any territory.
“New” calciﬁcation was seldom seen at 6 months
in those with no calcium at baseline. This only
occurred in 3 of 32 patients (9%) in the coronary
circulation and in the carotids in 5 of 102 patients
(5%). There was no incident calciﬁcation in those with
zero baseline scores in either the ascending aorta or
the aortic arch (Central Illustration).
Across both treatment groups, progression of SQRT
volumes >2.5 was noted in 12 of 32 patients (38%) in
the coronary arteries, 18 of 98 patients (18%) in the
aortic arch, and 3 of 104 patients (3%) in the carotid
arteries.
There was a trend toward greater progression of
calcium scores after SQRT transformation in the
aortic arch in those with nonzero scores at baseline
than in those with zero scores at baseline (p ¼ 0.055)
(Table 3).
Treatment assignment was not associated with a
signiﬁcant difference in progression of calcium scores
in any arterial territory (Table 4; similar data for
calcium volumes are not shown).
Comparing differences in absolute change in
average carotid PET indexes frombaseline to 6months,
TBR in active slices: p < 0.001; SHS: p ¼ 0.006; Mean-
MaxTBR: p¼0.003; andmeanMDS: p¼0.008declined
if baseline total carotid calcium was zero, relative to
those with nonzero scores (Table 5). At 6 months,
average carotid PET indexes consistently declined in
those with zero total carotid calcium scores (mean
active segment TBR: p < 0.001; SHS TBR: p ¼ 0.037;
mean MDS TBR: p < 0.001; and MeanMax TBR:
p ¼ 0.010) (Figure 1). There was no statistically sig-
niﬁcant change (p > 0.05) in these indexes for those
with nonzero scores. The presence or absence of
calciﬁcation elsewhere did not inﬂuence changes in
measurements of carotid PET uptake. Additionally,
there was no signiﬁcant relationship between baseline
calciﬁcation and change in measurements of inﬂam-
mation for the index vessel (ascending aorta in 75% of
cases [data not shown]).
DISCUSSION
The study investigated the relationship between
risk factors and vascular calciﬁcation in several
TABLE 2 Summary of Baseline Calcium Scores by Cardiovascular Risk Factors
Aortic Arch Coronary Arteries Total Carotid Arteries
n Score (AU) p Value* n Score (HU) p Value* n Score (HU) p Value*
Age, yrs #65 53 15 (0–280) <0.001 17 8 (0–21) 0.038 55 7 (0–100) <0.001
>65 45 651 (165–1181) 15 58 (0–204) 48 175 (18–427)
BMI, kg/m2 #29 48 261 (2–941) 0.107 14 10 (0–89) 0.750 50 132 (3–411) 0.007
>29 50 83 (0–775) 18 19 (0–76) 53 7 (0–158)
Coronary heart disease Yes 86 161 (0–797) 0.733 20 13 (0–111) 0.617 90 45 (0–267) 0.611
No 12 148 (2–860) 12 15 (0–67) 13 68 (0–249)
Hypertension Yes 74 165 (0–852) 0.705 24 10 (0–62) 0.078 79 54 (2–276) 0.750
No 24 57 (2–930) 8 53 (2–301) 24 13 (0–216)
Type 2 diabetes Yes 31 200 (0–1022) 0.457 15 4 (0–76) 0.488 32 41 (4–210) 0.565
No 67 135 (0–775) 17 21 (1–93) 71 54 (0–315)
Peripheral arterial disease Yes 13 280 (0–865) 0.249 5 10 (1–204) 0.562 13 100 (29–423) 0.128
No 85 135 (0–781) 27 16 (0–76) 90 49 (0–249)
Current smoker Yes 10 510 (43–1,079) 0.127 3 4 (0–10) 0.262 11 34 (4–173) 0.605
No 88 118 (0–789) 29 21 (0–89) 92 54 (0–272)
Ever smoked Yes 57 329 (43–1,073) 0.003 20 19 (1–109) 0.349 58 69 (4–276) 0.334
No 41 0 (0–551) 12 5 (0–67) 45 29 (0–224)
Metabolic syndrome Yes 53 157 (3–871) 0.650 20 13 (0–62) 0.495 57 25 (0–254) 0.185
No 45 166 (0–651) 12 29 (1–109) 46 106 (0–267)
HDL-C, mg/dl #40 38 214 (3–1,011) 0.549 11 47 (0–265) 0.279 42 27 (3–315) 0.683
>40 60 150 (0–753) 21 9 (0–48) 61 66 (0–254)
LDL-C, mg/dl #80 65 100 (0–775) 0.295 19 9 (0–204) 0.391 69 54 (0–276) 0.460
>80 33 200 (0–1,002) 13 23 (0–48) 34 33 (0–249)
Values are median (interquartile range). No data are given for the ascending aorta because calcium scores at baseline were zero in 71 of 80 participants. *p values are 2-sided
after square root transformation.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; other abbreviations as in Table 1.
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73arterial territories and explored the relationship
between baseline calciﬁcation and changes in
inﬂammation on serial [18F]FDG-PET/CT imaging
(Central Illustration). Whereas previous studies have
reported the relationship between arterial calciﬁca-
tion and cardiovascular risk factors and progression of
calciﬁcation in a single arterial territory (usually cor-
onary), the imaging undertaken in the dal-PLAQUE
study afforded an opportunity to examine both of
these questions. In addition, the ﬁrst data for pro-
gression of aortic calciﬁcation outside of renal disease
are reported.
Consistently, age >65 years was signiﬁcantly asso-
ciated with higher baseline arterial calciﬁcation.
Generally, the same cardiovascular risk factors inﬂu-
enced atherosclerosis in the coronary, aortic arch, and
carotid circulation, as also noted by other investigators
(3,15,16). Data from the Rotterdam study found that
age and current smoking were the strongest risk fac-
tors for calciﬁcation in all vessel beds, except for the
coronaries. Additionally, hypertension, hypercholes-
terolemia, and diabetes were independently related to
arterial calciﬁcation, although associations were not
consistent across all vessel beds and for men and
women (15). In a study by Rivera et al. (16), increasing
thoracic aortic scores were observed with increasingage. Most traditional cardiovascular risk factors,
including age, diabetes, hypertension, smoking, and
family history, were signiﬁcantly associated with the
presence of aortic calciﬁcation but not LDL-C or
HDL-C. Aortic calciﬁcation was also associated with
incident (new) coronary calciﬁcation and played a role
in predicting all-cause mortality (17) and cardiovas-
cular events, although not as strongly as coronary
artery calcium (18).
An inverse association between high BMI and
carotid arterial calciﬁcation was noted in our study.
Associations between BMI and vascular calciﬁcation
have generally been inconsistent (19–22), describing
positive, inverse, or no association. The “obesity
paradox” for cardiovascular risk is well described
(23). Although mechanistic insight is lacking, it has
been proposed that in females, estrogen production
in adipose tissue is relatively protective for the
vasculature (24).
Progression of vascular calciﬁcation has the
potential to better capture the temporal exposure to
risk factors compared with a single baseline score. It
has been suggested that a baseline calcium score can
be thought of as a single point on an atherosclerosis-
versus-time curve, whereas progression correlates
with the slope of that curve (25). Similarly, although
CENTRAL ILLUSTRATION Calciﬁcation Progression and Vascular Inﬂammation: A Substudy of the dal-PLAQUE Trial
Joshi, F.R. et al. J Am Coll Cardiol. 2016; 67(1):69–78.
Coronal CT, [18F]FDG-PET, and fused PET/CT images of the thorax and abdomen in a patient with established atherosclerosis are shown. White matter
([left panel CT] red arrows) is calcium within the atherosclerotic abdominal aorta. In the corresponding [18F]FDG-PET image (middle panel), there is little
overlap of [18F]FDG signal in this region, conﬁrmed on the fused image (right panel). In contrast, the ascending aorta ([middle and right panels] green
arrows) is not calciﬁed, but signiﬁcant [18F]FDG uptake is seen. This snapshot illustrates that inﬂammation and calciﬁcation rarely overlap. The present paper
extends these observations by highlighting the fact that different cardiovascular risk factors seem to drive vascular inﬂammation and calciﬁcation in the short
term. We examined this in multiple vascular beds. Calciﬁcation progression over time is rare without calcium at baseline (“calcium begets calcium”), but the
same does not apply to vascular inﬂammation. There was no effect on either pathological process of the HDL-raising therapy dalcetrapib. CT ¼ computed
tomography; [18F]FDG ¼ 18F-labeled ﬂuorodeoxyglucose; HDL ¼ high-density lipoprotein; PET ¼ positron emission tomography.
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74baseline scores might reﬂect atherosclerotic plaque
burden, progression might provide insight into
ongoing current disease activity. Rapid progression of
coronary calcium scores is independently predictive
of mortality (13). Our study demonstrated very little
newly detectable calciﬁcation at 6 months in those
without it at baseline, presumably due to the rela-
tively short interval between scans. Nevertheless, our
data are consistent with those of Min et al. (26), whodemonstrated that in subjects over 45 years of age,
approximately 5% of those without detectable coro-
nary calcium on CT would develop it over 12 months,
largely dependent on the number of cardiovascular
risk factors present.
In those with some degree of calcium at baseline,
there were larger increases in calcium scores within
the aortic arch and right carotid arteries than in those
with nonzero scores in the same arteries at the start of
TABLE 3 Progression in Vascular Calciﬁcation Over 6 Months by Baseline
(Zero vs. Nonzero) Calcium Score and Volume
Zero at Baseline Nonzero at Baseline
p Value*n (%)
Median Absolute
Change n (%)
Median Absolute
Change
Calcium scores (AU)
Ascending aorta 71 (89) 0 (0 to 0) 9 (11) 0 (10 to 29) 0.900
Aortic arch 29 (30) 0 (0 to 0) 69 (70) 13 (15 to 138) 0.055
Coronary arteries 11 (34) 0 (0 to 0) 21 (66) 10 (5 to 68) 0.414
Left carotid 39 (38) 0 (0 to 0) 64 (62) 0 (11 to 21) 0.774
Right carotid 43 (42) 0 (0 to 0) 59 (58) 5 (2 to 23) 0.029
Total carotid arteries 28 (27) 0 (0 to 0) 74 (73) 3 (5 to 33) 0.249
Calcium volumes, mm3
Ascending aorta 71 (89) 0 (0 to 0) 9 (11) 3 (11 to 9) 0.536
Aortic arch 29 (30) 0 (0 to 0) 69 (70) 14 (35 to 121) 0.356
Coronary arteries 11 (34) 0 (0 to 0) 21 (66) 6 (17 to 187) 0.648
Left carotid 39 (38) 0 (0 to 0) 64 (62) 4 (8 to 23) 0.995
Right carotid 43 (42) 0 (0 to 0) 59 (58) 8 (3 to 34) 0.006
Total carotid arteries 28 0 (0 to 0) 74 10 (8 to 31) 0.225
Values are n (%) and median (interquartile range). *p values are 2-sided after square root transformation.
AU ¼ Agatston units.
TABLE 4 Effect of Treatment With Dalcetrapib on Progression of Calcium Scores
Over 6 Months
Absolute Change
From Baseline (95% CI)* p Value
Change from Baseline
After SQRT (95% CI)* p Value
Ascending aorta 6 (19 to 7) 0.355 0.17 (0.73 to 0.38) 0.538
Aortic arch 83 (4 to 171) 0.061 0.74 (0.54 to 2.02) 0.254
Coronary arteries 61 (171 to 48) 0.263 1.51 (4.64 to 1.61) 0.330
Total carotid arteries 6 (10 to 21) 0.459 0.28 (0.18 to 0.74) 0.231
Values are differences from placebo with 95% CI; p values are 2-sided. *Absolute change in Agatston units.
SQRT ¼ square root-transformed values.
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75the study. To the best of our knowledge, these are the
ﬁrst published data for the progression of aortic
calciﬁcation outside of the context of end-stage
kidney disease or renal transplantation (27).
Van Gils et al. (28) described the progression of
carotid calciﬁcation in patients after transient
ischemic attack or stroke, with 4.7 years between
scans. Calciﬁcation was measured on contrast-
enhanced CT scans using a threshold of 600 Houns-
ﬁeld units to deﬁne calcium. Incident calciﬁcation
was seen in approximately 40% of those with zero
calcium at baseline over the follow-up period and was
associated with advanced age and hypertension at
baseline. Similarly, the most important determinant
of progression of existing calciﬁcation was the
baseline calcium score, although age, diabetes, hy-
pertension, and smoking were also signiﬁcantly
associated. There are no published data for the
prognostic implications of carotid artery calciﬁcation.
Data regarding its relationship to luminal stenosis are
conﬂicting (29,30).
There were no signiﬁcant differences in progres-
sion of vascular calciﬁcation in any arterial territory
with dalcetrapib compared to that with placebo.
In vitro, HDL-C inhibits osteogenic differentiation
and calciﬁcation of vascular smooth muscle cells (31).
Kuller et al. (32) found an independent association
between HDL-C and coronary calciﬁcation in post-
menopausal females, although there is no evidence
for an association with calciﬁcation elsewhere (15).
Use of [18F]NaF has been advocated as a means of
noninvasively detecting active calciﬁcation in vivo
(33). 18F-NaF uptake in the coronary arteries in that
study (33) was associated with low HDL-C, suggesting
that this might be permissive for progressive calciﬁ-
cation. Further research is required to investigate
this; to date, however, pharmacological treatment
of low HDL-C has not inﬂuenced clinical outcomes
(34,35).
Over the 6-month interval from ﬁrst to last PET
scan in the dal-PLAQUE study, carotid artery TBR
indexes consistently declined in patients without
carotid calciﬁcation at baseline but remained statis-
tically unchanged when calciﬁcation was already
present. Calciﬁcation in other arterial territories did
not appear to inﬂuence changes in carotid inﬂam-
mation, suggesting a local interaction. Inﬂamma-
tion and calciﬁcation are thought to be active at
different phases of the disease process in athero-
sclerosis. Inﬂammation appears to be dominant early,
leading to development and maturation of plaques,
with calciﬁcation predominant later. Pre-clinical
models have demonstrated this spatial and temp-
oral relationship (2). Initial deposition of calciumhydroxyapatite, so-called microcalciﬁcation, may
induce further inﬂammatory responses (36). Although
they are linked, inﬂammation and calciﬁcation are
distinct processes within atherosclerosis, and
medium-term changes in the relative importance of
each in vivo are not well understood. Recent work by
Abdelbaky et al. (37) suggests that local vascular
inﬂammation, as assessed by [18F]FDG-PET, is inde-
pendently associated with progression of thoracic
aortic calciﬁcation. In the current study, arterial
segments with subsequent incident calciﬁcation had
the highest baseline [18F]FDG uptake, suggesting that
inﬂammation precedes calciﬁcation. Furthermore,
within individual patients, arterial segments with
progressive calciﬁcation from a nonzero baseline had
the highest [18F]FDG uptake. This suggests that
inﬂammation continues to be important after the
development of macroscopic calciﬁcation. Segments
with calciﬁcation that did not progress had the
lowest [18F]FDG uptake. This is consistent with
TABLE 5 Change in Carotid [18F]FDG-PET Indices From Baseline
to 6 Months for Patients With Zero and Nonzero Baseline Total
Carotid Calcium Scores
Mean Difference (95% CI) p Value
Mean active segment TBR 0.23 (0.35 to 0.11) <0.001
Single hottest slice TBR 0.24 (0.41 to 0.07) 0.006
Mean MDS TBR 0.18 (0.31 to 0.05) 0.008
MeanMax TBR 0.18 (0.30 to 0.06) 0.003
Values are mean differences (zero baseline scores minus nonzero) with 95% CI;
2-sided p values.
[18F]FDG ¼ 18F-labeled ﬂuorodeoxyglucose; MDS ¼ most diseased segment;
MeanMax ¼ mean of maximum; TBR ¼ target-to-background ratio.
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76previous work showing that the ﬁnal stages of calci-
ﬁcation are associated with a reduction in inﬂam-
matory activity (38). The point at which
inﬂammation becomes less prominent, however, hasFIGURE 1 Vascular Calciﬁcation and Vascular Inﬂammation: Change
6 Months by Baseline Total Carotid Calcium Score (Zero or Nonzero)
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conﬁdence intervals are shown for absolute change from baseline. Two-
total (sum left and right) carotid calcium scores were dichotomized into
MeanMax ¼ mean of maximum; TBR ¼ target-to-background ratio.yet to be deﬁned. [18F]NaF uptake holds promise as
a means of imaging active calciﬁcation in vivo (39),
and further longitudinal study of changes in the
activity of both inﬂammation and calciﬁcation is
needed to better understand these processes.
STUDY LIMITATIONS. This was a post-hoc analysis of
data from the dal-PLAQUE study, with only 6 months
between PET/CT imaging sessions. Consequently,
despite the inclusion of a high-risk population, there
was relatively little progression of vascular calciﬁ-
cation during this short window. A signiﬁcant num-
ber of scans were excluded from analysis of the
coronary arteries because of prior coronary bypass
surgery or coronary intervention. Whereas coronary
calcium scores on electrocardiogram-gated and
ungated CT scans are highly correlated, the inter-
scan variability on ungated scans is not known.in Average Carotid [18F]FDG PET Indexes From Baseline at 3 and
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.001; nonzero score p ¼ 0.399. (B) Change in single hottest slice TBR.
mean MDS TBR. Zero calcium score p <0.001; nonzero score
; nonzero score p ¼ 0.095. Least squares means and 95%
sided p values are given for changes at 6 months from baseline for
zero (blue) and nonzero (orange). MDS ¼ most diseased segment;
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In several
vascular territories, evidence of inﬂammation detected by serial
[18F]FDG-PET/CT imaging appears to precede arterial calciﬁca-
tion, and the intensity of [18F]FDG uptake is associated with the
rate of progression of arterial calciﬁcation, but temporal rela-
tionships vary from one arterial region to another.
TRANSLATIONAL OUTLOOK: Longer-term studies are
needed to explore the relationships among vascular inﬂamma-
tion, calciﬁcation, and clinical ischemic events.
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77Comparison of ungated scans, therefore, may miss
small increments in coronary calcium scores, but this
is likely to be less of a problem in the other vascular
beds studied. Finally, as in any post-hoc data anal-
ysis, false positive ﬁndings are possible. We advise
caution in interpretation of our results, which
need to be replicated in longer, larger, prospective
studies.
CONCLUSIONS
Inﬂammation and calciﬁcation are important in both
the progression of atherosclerosis and its clinical
complications. In this study, we have described the
relationship between cardiovascular risk factors and
both baseline and interval calciﬁcation in several
arterial beds, as well as the interactions with inﬂam-
mation in those territories. We have also provided
data concerning the drivers of calciﬁcation progres-
sion and lack of a signiﬁcant effect of an HDL-raising
therapy on calciﬁcation. Finally, we have provided
the ﬁrst report of aortic calciﬁcation progression
outside of the context of subjects with renal failure.
These ﬁndings are important for providing a better
understanding of the links between these patholog-
ical processes and could help to improve patient riskstratiﬁcation and provide a platform for developing
and testing new atherosclerosis treatments.
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